Regenacy Pharma snags $30M for diabetic neuropathy treatment

blue illustration of neurons
Regenacy’s treatment, ricolinostat, is a pill that inhibits histone deacetylase 6. (Colin Behrens)

Treatments for diabetic peripheral neuropathy—nerve damage stemming from diabetes—tend to focus on managing pain. But Regenacy Pharmaceuticals’ approach aims to reverse the nerve damage that causes that pain, and the company has scored $30 million to push its program into phase 2.

People with diabetes may develop peripheral neuropathy over time as high levels of sugars and fats in the blood damage their nerves. Patients feel pain most commonly in the fingers, arms, legs and feet and may eventually lose feeling in those areas, which can lead to serious infections. Addressing diabetes is a major part of treating diabetic neuropathy, but there is no treatment that reverses nerve damage.

RELATED: Neurogene nets $68.5M to advance gene therapies for rare neurological diseases

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Regenacy’s treatment, ricolinostat, is a pill that inhibits histone deacetylase 6 (HDAC6). Blocking this enzyme restores the function of microtubules, known as the “railways” cells use to transport energy and nutrients. A disease like diabetes or neurotoxic drugs used in chemotherapy can disrupt this transport, causing nerve damage.

“We are fortunate to have the strong support of investors aligned with our mission to provide lasting relief of all symptoms of diabetic peripheral neuropathy,” Regenacy CEO Simon Jones, Ph.D., said in a statement. “Our preclinical studies demonstrate that selectively inhibiting HDAC6 has the potential to safely restore nerve function in multiple peripheral neuropathies, and we are looking forward to advancing our lead program into phase 2 studies this year.”

RELATED: Peripheral neuropathy could be reversed by FDA-approved class of drugs

Cobro Ventures and Taiwania Capital Management led the series A round, with 3E Bioventures Capital, Yonjin Capital, Viva Biotech Holdings and Ta Ya Venture Holdings also chipping in.

“Regenacy is diligently working on developing a therapeutic that addresses the underlying causes of peripheral neuropathy,” Marc Cohen, Regenacy’s executive chairman and co-founder of Cobro Ventures, said. “We believe the company’s HDAC6 approach has a strong potential to provide long-term improvements in pain, motor function and sensitivity in patients with this disease.”

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.